Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis

Mark R. Deneau, Cara Mack, Douglas Mogul, Emily R. Perito, Pamela L. Valentino, Achiya Z. Amir, Matthew DiGuglielmo, Laura G. Draijer, Wael El-Matary, Katryn N. Furuya, Nitika Gupta, Jessica T. Hochberg, Simon Horslen, M. Kyle Jensen, Maureen M. Jonas, Nanda Kerkar, Bart G.P. Koot, Trevor J. Laborda, Christine K. Lee, Kathleen M. LoomesMercedes Martinez, Alexander Miethke, Tamir Miloh, Saeed Mohammad, Nadia Ovchinsky, Girish Rao, Amanda Ricciuto, Pushpa Sathya, Kathleen B. Schwarz, Uzma Shah, Ruchi Singh, Bernadette Vitola, Andréanne Zizzo, Stephen L. Guthery

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Aims: Many children with primary sclerosing cholangitis (PSC) receive oral vancomycin therapy (OVT) or ursodeoxycholic acid (UDCA). There is a paucity of data on whether these medications improve outcomes. Approach and Results: We analyzed retrospective data from the Pediatric PSC Consortium. Children treated with OVT were matched 1:1:1 to those treated with UDCA or managed with observation (no treatment) based on the closest propensity score, ensuring similar baseline characteristics. Two hundred sixty-four patients (88 each with OVT, UDCA, or observation) had matching propensity scores and were similar in demographics, phenotype, immunosuppression, baseline biochemistry, and hepatic fibrosis. After 1 year in an intention-to-treat analysis, all outcome metrics were similar regardless of treatment group. In OVT, UDCA, and untreated groups, respectively: Gamma-glutamyltransferase normalized in 53%, 49%, and 52% (P = not significant [NS]), liver fibrosis stage was improved in 20%, 13%, and 18% and worsened in 11%, 29%, and 18% (P = NS), and the 5-year probability of liver transplant listing was 21%, 10%, and 12% (P = NS). Favorable outcome was associated with having a mild phenotype of PSC and minimal hepatic fibrosis. Conclusions: We presented the largest-ever description of outcomes on OVT in PSC and compared them to carefully matched patients on UDCA or no therapy. Neither OVT nor UDCA showed improvement in outcomes compared to a strategy of observation. Patients progressed to end-stage liver disease at similar rates. Spontaneous normalization of biochemistry is common in children receiving no therapy, particularly in the majority of children with a mild phenotype and an early stage of disease. Placebo-controlled treatment trials are needed to identify effective treatments for pediatric PSC.

Original languageEnglish (US)
Pages (from-to)1061-1073
Number of pages13
JournalHepatology
Volume73
Issue number3
DOIs
StatePublished - Mar 2021

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis'. Together they form a unique fingerprint.

Cite this